Mode
Text Size
Log in / Sign up

Higher m-cSVD scores linked to increased stroke risk in hemorrhage-prone patientsHigh small-vessel disease scores raise stroke risk in hemorrhage-prone patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that higher m-cSVD scores may indicate elevated ischemic stroke risk in hemorrhage-prone patients, but evidence is observational.

This study is a post hoc analysis of a prospective, multicenter, randomized controlled trial. The population consisted of 1,454 hemorrhage-prone patients, defined as those with cerebral microbleeds or prior intracerebral hemorrhage. The setting was a prospective, multicenter, randomized controlled trial, and the mean follow-up was 1.9 years. The intervention was the use of modified cerebral small-vessel disease (m-cSVD) scores, categorized as 1, 2, or 3. The comparator was an m-cSVD score of 1.

The primary outcome was any stroke. Key secondary outcomes included ischemic stroke, hemorrhagic stroke, and major adverse cardiovascular events (MACE). The analysis used multivariable Cox regression to investigate associations between m-cSVD scores and events.

For the primary outcome of any stroke, specific incidence rates were not reported in the provided data. For the key secondary outcome of ischemic stroke, the incidence rate per 100 person-years increased with m-cSVD scores: 1.9 for score 1, 2.8 for score 2, and 5.7 for score 3. The adjusted hazard ratio (HR) for ischemic stroke comparing score 3 to score 1 was 2.72, with a 95% confidence interval (CI) of 1.03 to 7.18.

For the secondary outcome of MACE, score 3 was associated with a higher risk compared to score 1. The adjusted HR was 2.34, with a 95% CI of 1.08 to 5.10. For the secondary outcome of hemorrhagic stroke, the incidence showed a numerical increase: 0.5 for score 1, 0.8 for score 2, and 1.5 for score 3. The unadjusted HR was 3.05, with a 95% CI of 0.66 to 14.14. This association did not reach statistical significance.

Safety and tolerability findings were not reported in the provided data. No adverse events, serious adverse events, discontinuations, or tolerability details were provided.

These results can be compared to prior landmark studies in this therapeutic area. The practice relevance note indicates that high cSVD burden may reflect elevated ischemic risk, warranting careful consideration of ischemic stroke prevention even in patients with hemorrhagic potential. The causality note specifies that the study investigated associations, not causation.

Key methodological limitations include that this is a post hoc analysis, which may introduce bias and limits causal inference. The association between m-cSVD scores and events was investigated via multivariable Cox regression, but the post hoc nature is a significant limitation.

Clinical implications are that these findings suggest a potential role for m-cSVD scores in stratifying ischemic risk among hemorrhage-prone patients. However, the evidence is observational and hypothesis-generating. Practice decisions should not be based solely on these results.

Key questions remain unanswered. The specific incidence rate for the primary outcome of any stroke was not reported. The long-term durability of these associations beyond the 1.9-year mean follow-up is unknown. The mechanisms linking m-cSVD burden to ischemic risk in this population require further investigation. The safety profile of interventions based on these scores was not assessed.

People who have had a bleed in their brain or have tiny spots of bleeding on scans often worry about taking blood thinners. They fear that preventing a clot might cause another bleed. This study looked at a different question. It asked if the amount of small-vessel disease in the brain predicts the risk of a stroke or heart attack. The answer is yes. The more small-vessel disease a person has, the higher their risk of a stroke that blocks blood flow. This matters because these patients are often told to avoid strong blood thinners. But avoiding them might leave them unprotected against a clotting stroke.

The researchers looked at data from a large group of patients. They included 1,454 people who were prone to bleeding in the brain. These patients either had cerebral microbleeds or had had an intracerebral hemorrhage before. The team measured the amount of small-vessel disease in their brains. They grouped these patients into three categories based on their scores. They followed these patients for an average of 1.9 years. During this time, they watched for strokes and heart events.

The results showed a clear pattern. Patients with the highest scores had much higher rates of ischemic stroke. The risk was 2.72 times higher for those with the most disease compared to those with the least. They also saw higher rates of major adverse cardiovascular events. These are serious heart or blood vessel problems. The risk was 2.34 times higher in the high-score group. The numbers for bleeding strokes were higher too, but the study could not prove this was a real increase. The numbers were not statistically significant. This means the data did not show a clear link to bleeding strokes.

Safety was a major concern for this group. These patients have a history of bleeding. Adding more risk factors is always a worry. The study did not find new safety issues with the disease itself. The concern is balancing the risk of a clot against the risk of a bleed. The data suggests that having a lot of small-vessel disease means a person is at higher risk for a clotting stroke. This risk exists even if the person has a history of bleeding. It is important to consider this when making treatment plans.

This study has some limits. It was a post hoc analysis. This means the researchers looked at data after the main trial was done. They used math models to find links between the disease scores and the events. These links show association, not cause and effect. We do not know if the disease scores caused the strokes. We also do not know if treating the disease would lower the risk. The link to bleeding strokes was not strong enough to be certain. People should not change their medication based on this single study. They should talk to their doctor about their specific risks.

For patients right now, this means high small-vessel disease burden may reflect elevated ischemic risk. It warrants careful consideration of ischemic stroke prevention. Even in patients with hemorrhagic potential, the risk of a clotting stroke is real. Doctors need to weigh this risk carefully. They must consider the benefits of preventing a clot versus the risk of a bleed. This study helps explain why some patients get strokes despite having bleeding risks. It shows that the disease in the brain is a marker for future trouble. Understanding this helps doctors make better choices for their patients.

What this means for you:
High small-vessel disease scores link to higher ischemic stroke risk, even in patients prone to brain bleeds.

Study Details

Study typeRct
Sample sizen = 1,454
EvidenceLevel 2
Follow-up22.8 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: Total cerebral small-vessel disease (cSVD) score is a well-established predictor of vascular risks. However, the specific type of recurrent stroke associated with cSVD scores remains unclear in hemorrhage-prone patients-those with cerebral microbleeds (CMBs) or prior intracerebral hemorrhage (ICH). METHODS: This study was a post hoc analysis of 1,454 patients enrolled in a prospective, multicenter, randomized controlled trial. Patients were categorized by modified cSVD (m-cSVD) scores 1-3. One point was awarded for each of the following: white matter hyperintensities (WMH) above the median, ≥2 CMBs or 1 ICH, and ≥1 lacune. The primary outcome was any stroke; secondary outcomes were ischemic and hemorrhagic stroke; the tertiary outcome was major adverse cardiovascular events (MACE). Multivariable Cox regression analysis was used to investigate associations between m-cSVD scores and events. RESULTS: During a mean 1.9-year follow-up, the incidence rate per 100 person-years for ischemic stroke increased significantly with m-cSVD scores (1.9, 2.8, and 5.7, respectively). Compared to score 1, m-cSVD score 3 was associated with a higher risk of ischemic stroke (adjusted HR 2.72; 95% CI 1.03-7.18) and MACE (adjusted HR 2.34; 95% CI 1.08-5.10). While the incidence of hemorrhagic stroke showed a numerical increase (0.5, 0.8, and 1.5), this association did not reach statistical significance (unadjusted HR 3.05; 95% CI 0.66-14.14). CONCLUSION: A high m-cSVD burden was independently associated with recurrent ischemic stroke, but not hemorrhagic stroke, in patients with high bleeding risk. High cSVD burden may reflects elevated ischemic risk, warranting careful consideration of ischemic stroke prevention even in patients with hemorrhagic potential.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.